CANSINOBIO (06185) Income Statement & Earnings

23.380
-0.400-1.68%

15min DelayMarket Closed Jul 24 16:07 CST

5.78BMarket Cap-4676.00P/E (TTM)

CANSINOBIO (06185) Income Statement

Cumulative·All

YOY

Hide blank lines

Currency: CNY

2026/Q1

2025/FY

2025/Q9

2025/H1

2025/Q1

2024/FY

2024/Q9

2024/H1

2024/Q1

2023/FY

2023/Q9

2023/H1

2023/Q1

2022/FY

2022/Q9

2022/H1

2022/Q1

2021/FY

2021/Q9

2021/H1

Total Revenue

+38.73%190.28M

+28.43%1.06B

+22.13%692.57M

+31.07%374.09M

+20.02%137.16M

+138.97%824.88M

+222.88%567.08M

+1253.60%285.42M

+13.65%114.28M

-66.52%345.18M

-75.17%175.63M

-96.65%21.09M

-79.86%100.55M

-76.02%1.03B

-77.08%707.40M

-69.45%629.79M

+6.98%499.36M

+23086.49%4.30B

+54286.51%3.09B

--2.06B

Operating Revenue

+38.73%190.28M

+28.43%1.06B

+22.13%692.57M

+31.07%374.09M

+20.02%137.16M

+138.97%824.88M

+222.88%567.08M

+1253.60%285.42M

+13.65%114.28M

-66.52%345.18M

-75.17%175.63M

-96.65%21.09M

-79.86%100.55M

-76.02%1.03B

-77.08%707.40M

-69.45%629.79M

+6.98%499.36M

+23086.49%4.30B

+54286.51%3.09B

--2.06B

Cost of Revenue

-52.72%-36.26M

-6.42%-260.13M

+8.50%-133.86M

+21.13%-77.51M

+48.64%-23.74M

+79.98%-244.43M

+15.30%-146.28M

+87.68%-98.27M

+29.08%-46.23M

-0.29%-1.22B

+28.54%-172.72M

-154.31%-797.57M

+56.10%-65.19M

+6.17%-1.22B

+76.91%-241.69M

+49.85%-313.62M

+33.73%-148.47M

-9301.40%-1.30B

-207805.96%-1.05B

---625.30M

Cost of Goods Sold

----

-6.42%-260.13M

----

+21.13%-77.51M

----

+79.98%-244.43M

----

+87.68%-98.27M

----

-0.29%-1.22B

----

-154.31%-797.57M

----

+6.17%-1.22B

----

+49.85%-313.62M

----

-9301.40%-1.30B

----

---625.30M

Gross Profit

+35.80%154.02M

+37.70%799.26M

+32.78%558.71M

+58.47%296.58M

+66.67%113.42M

+166.26%580.45M

+14344.25%420.79M

+124.10%187.15M

+92.41%68.05M

-369.45%-876.02M

-99.37%2.91M

-345.59%-776.49M

-89.92%35.37M

-106.22%-186.61M

-77.16%465.71M

-77.98%316.17M

+44.57%350.88M

+63231.92%3.00B

+39339.44%2.04B

--1.44B

Operating Expense

-8.97%-190.00M

+7.97%-915.39M

-2.77%-633.97M

+1.49%-394.25M

+11.73%-174.36M

+23.54%-994.68M

+62.84%-616.86M

+36.22%-400.22M

+27.11%-197.54M

+2.32%-1.30B

-15.53%-1.66B

-12.64%-627.53M

-5.39%-271.00M

-9.32%-1.33B

-72.13%-1.44B

+17.63%-557.12M

+12.13%-257.14M

-130.58%-1.22B

-270.02%-834.69M

-373.17%-676.40M

Selling Expenses

-38.21%-81.08M

-12.92%-416.73M

-41.41%-277.22M

-39.00%-156.34M

-25.92%-58.66M

-4.43%-369.05M

-1.24%-196.04M

+12.70%-112.48M

+15.27%-46.59M

-32.55%-353.40M

-29.84%-193.63M

-44.93%-128.84M

-60.25%-54.98M

-151.95%-266.61M

-132.61%-149.14M

-157.07%-88.90M

-378.52%-34.31M

-538.92%-105.82M

-689.03%-64.11M

-673.30%-34.58M

Administrative Expenses

-2.30%-35.77M

+10.93%-173.11M

+6.29%-110.05M

+11.41%-77.76M

+5.66%-34.97M

+33.99%-194.36M

+37.57%-117.43M

+37.33%-87.78M

+38.78%-37.07M

-5.89%-294.45M

+11.11%-188.09M

-0.30%-140.05M

+5.54%-60.55M

-19.95%-278.07M

-49.97%-211.61M

-54.35%-139.63M

-330.93%-64.10M

-179.71%-231.81M

-178.05%-141.11M

-196.06%-90.46M

Research and Development Expenses

+1.79%-71.41M

+24.77%-313.04M

+17.48%-224.67M

+20.50%-147.79M

+24.84%-72.71M

+34.78%-416.12M

+41.02%-272.27M

+45.06%-185.90M

+35.40%-96.75M

+18.02%-637.99M

+15.92%-461.67M

-4.45%-338.37M

+4.70%-149.77M

+11.43%-778.26M

+16.27%-549.07M

+41.23%-323.97M

+41.75%-157.16M

-105.08%-878.72M

-271.09%-655.77M

-410.81%-551.28M

Impairment and Provision

+56.90%-4.66M

+17.40%-12.52M

-9.52%-26.18M

+12.12%-12.36M

+28.24%-10.80M

-0.70%-15.15M

+97.02%-23.90M

+30.59%-14.06M

-16.94%-15.05M

-71.43%-15.05M

-50.46%-801.12M

-338.13%-20.26M

-108.88%-12.87M

-381.20%-8.78M

-11281.90%-532.45M

-6148.65%-4.62M

-76937.50%-6.16M

-366.50%-1.82M

---4.68M

---74.00K

-Impairment Losses of Other Assets

+56.90%-4.66M

+17.40%-12.52M

-9.52%-26.18M

+12.12%-12.36M

+28.24%-10.80M

-0.70%-15.15M

+97.02%-23.90M

+30.59%-14.06M

-16.94%-15.05M

-71.43%-15.05M

-50.46%-801.12M

-338.13%-20.26M

-108.88%-12.87M

-381.20%-8.78M

-11281.90%-532.45M

-6148.65%-4.62M

-76937.50%-6.16M

-366.50%-1.82M

---4.68M

---74.00K

Revaluation Surplus

+7.93%2.91M

----

+157.01%4.10M

----

+229.10%2.70M

----

+53.23%-7.19M

----

-129.16%-2.09M

----

-379.50%-15.37M

----

+56.11%7.17M

----

-82.25%5.50M

----

+670.43%4.59M

----

+209.47%30.98M

----

-Changes in The Fair Value of Other Assets

+7.93%2.91M

----

+157.01%4.10M

----

+229.10%2.70M

----

+53.23%-7.19M

----

-129.16%-2.09M

----

-379.50%-15.37M

----

+56.11%7.17M

----

-82.25%5.50M

----

+670.43%4.59M

----

+209.47%30.98M

----

Profit from Asset Sales

----

+281.80%42.96K

----

--84.72K

----

-163.08%-23.63K

----

--37.46K

----

Special Items of Operating Income

-71.99%14.16M

+1379.74%160.39M

+601.99%115.54M

+355.24%95.46M

+175.68%50.55M

-92.35%10.84M

-113.76%-23.02M

-160.73%-37.40M

-230.88%-66.79M

-5.26%141.72M

+44.00%167.28M

-19.13%61.58M

+31.82%51.03M

+16.99%149.58M

+204.12%116.16M

+78.83%76.15M

+499.30%38.72M

+4.19%127.85M

+13.35%38.20M

+113.43%42.58M

Operating Profit

-98.20%-25.08M

+110.97%44.26M

+113.15%29.72M

+99.12%-2.21M

+93.62%-12.66M

+80.18%-403.39M

+84.89%-225.94M

+81.34%-250.47M

-6.28%-198.26M

-48.69%-2.04B

-73.96%-1.50B

-714.58%-1.34B

-242.43%-186.54M

-171.60%-1.37B

-169.67%-859.78M

-120.54%-164.80M

+391.65%130.97M

+576.88%1.91B

+751.39%1.23B

+752.30%802.33M

Financing Income

-22.37%7.84M

-57.78%34.77M

-53.43%23.90M

-67.97%17.33M

-56.90%10.10M

-31.74%82.35M

-31.75%51.32M

-38.87%54.09M

+4.06%23.43M

-46.75%120.64M

+68.53%75.20M

-36.10%88.49M

+59.89%22.52M

+184.45%226.57M

-28.28%44.62M

+235.72%138.49M

-37.03%14.08M

+151.10%79.65M

+390.56%62.22M

+97.85%41.25M

Financing Cost

+44.77%-7.19M

+4.77%-57.29M

+23.21%-36.40M

-4.87%-34.42M

+11.29%-13.02M

+6.50%-60.16M

-3.15%-47.41M

-11.65%-32.82M

-67.46%-14.67M

-53.82%-64.34M

-66.83%-45.96M

-92.87%-29.40M

+7.22%-8.76M

+23.21%-41.83M

-121.50%-27.55M

-125.86%-15.24M

-465.51%-9.44M

-98.09%-54.48M

---12.44M

-13671.43%-6.75M

Pretax Profit

-107.18%-34.38M

+105.70%21.74M

+103.76%8.49M

+91.58%-19.30M

+90.51%-16.59M

+80.74%-381.20M

+84.50%-225.70M

+82.14%-229.20M

+12.76%-174.88M

-67.14%-1.98B

-125.10%-1.46B

-2988.28%-1.28B

-265.82%-200.47M

-161.13%-1.18B

-150.13%-646.85M

-104.97%-41.56M

+867.49%120.90M

+588.30%1.94B

+833.63%1.29B

+918.81%836.83M

Special Items of Pretax Income

+63.39%-40.92K

----

+82.44%-504.64K

----

-6398.83%-111.76K

----

+92.94%-2.87M

----

+99.98%-1.72K

----

-3128.89%-40.70M

----

-729.24%-8.12M

----

+74.07%-1.26M

----

-323.52%-979.00K

----

-703.60%-4.86M

----

Tax

----

+348.68%6.14M

----

+703.53%5.82M

----

-121.54%-2.47M

----

-182.82%-964.00K

----

-94.78%11.45M

----

-97.98%1.16M

----

+838.17%219.24M

----

-42.57%57.60M

----

---29.70M

----

--100.30M

Net Profit

-250.13%-40.42M

+107.26%27.87M

+106.36%14.44M

+94.14%-13.49M

+93.40%-11.55M

+80.50%-383.67M

+84.38%-227.20M

+82.05%-230.16M

-2.75%-174.88M

-103.93%-1.97B

-197.72%-1.45B

-8092.09%-1.28B

-248.91%-170.20M

-150.59%-964.76M

-136.64%-488.68M

-98.29%16.04M

+825.59%114.30M

+580.81%1.91B

+858.36%1.33B

+1016.95%937.13M

Profit from Continuing Operations

-250.13%-40.42M

+107.26%27.87M

+106.36%14.44M

+94.14%-13.49M

+93.40%-11.55M

+80.50%-383.67M

+84.38%-227.20M

+82.05%-230.16M

-2.75%-174.88M

-103.93%-1.97B

-197.72%-1.45B

-8092.09%-1.28B

-248.91%-170.20M

-150.59%-964.76M

-136.64%-488.68M

-98.29%16.04M

+825.59%114.30M

+580.81%1.91B

+858.36%1.33B

+1016.95%937.13M

Minority Interests

----

+99.01%-4.79M

+98.98%-4.79M

+98.91%-4.79M

+84.38%-4.79M

-776.08%-484.70M

-3192.65%-469.89M

-11683.23%-440.74M

-330.62%-30.65M

-657.48%-55.33M

---14.27M

--3.81M

-334.55%-7.12M

---7.30M

----

Net Income to Parent Company

-250.13%-40.42M

+107.36%27.87M

+106.49%14.44M

+94.02%-13.49M

+93.21%-11.55M

+74.45%-378.88M

+77.42%-222.41M

+73.22%-225.37M

-21.89%-170.10M

-63.04%-1.48B

-107.63%-985.03M

-6975.54%-841.43M

-214.94%-139.55M

-147.51%-909.43M

-135.57%-474.41M

-98.69%12.24M

+960.23%121.41M

+582.65%1.91B

+858.36%1.33B

+1016.95%937.13M

Net Income to Common Stockholders

-250.13%-40.42M

+107.36%27.87M

+106.49%14.44M

+94.02%-13.49M

+93.21%-11.55M

+74.45%-378.88M

+77.42%-222.41M

+73.22%-225.37M

-21.89%-170.10M

-63.04%-1.48B

-107.63%-985.03M

-6975.54%-841.43M

-214.94%-139.55M

-147.51%-909.43M

-135.57%-474.41M

-98.69%12.24M

+960.23%121.41M

+582.65%1.91B

+858.36%1.33B

+1016.95%937.13M

Basic EPS

-220.00%-0.16

+107.19%0.11

+106.67%0.06

+94.51%-0.05

+92.75%-0.05

+74.54%-1.53

+77.44%-0.90

+73.31%-0.91

-21.05%-0.69

-63.32%-6.01

-107.81%-3.99

-6920.00%-3.41

-216.33%-0.57

-147.55%-3.68

-135.62%-1.92

-98.68%0.05

+916.67%0.49

+550.00%7.74

+791.03%5.39

+923.30%3.79

Diluted EPS

-220.00%-0.16

+107.19%0.11

+106.67%0.06

+94.51%-0.05

+92.75%-0.05

+74.54%-1.53

+77.44%-0.90

+73.31%-0.91

-21.05%-0.69

-63.32%-6.01

-107.81%-3.99

-6920.00%-3.41

-216.33%-0.57

-147.55%-3.68

-135.62%-1.92

-98.68%0.05

+916.67%0.49

+550.00%7.74

+791.03%5.39

+923.30%3.79

Deadline

Mar 31, 2026

Dec 31, 2025

Sep 30, 2025

Jun 30, 2025

Mar 31, 2025

Dec 31, 2024

Sep 30, 2024

Jun 30, 2024

Mar 31, 2024

Dec 31, 2023

Sep 30, 2023

Jun 30, 2023

Mar 31, 2023

Dec 31, 2022

Sep 30, 2022

Jun 30, 2022

Mar 31, 2022

Dec 31, 2021

Sep 30, 2021

Jun 30, 2021

Accounting Standard

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

Audit Opinions

	2026/Q1	2025/FY	2025/Q9	2025/H1	2025/Q1	2024/FY	2024/Q9	2024/H1	2024/Q1	2023/FY	2023/Q9	2023/H1	2023/Q1	2022/FY	2022/Q9	2022/H1	2022/Q1	2021/FY	2021/Q9	2021/H1

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"